News Story: Full Text
Sponsored By
AbbVie
Please Click On The Above Banner For More Details
Braintumor Website

 

Supplement to "Seminars in Oncology" devoted to NovoTTF-100A.

Al's Comment:

This supplement publishes 4 research papers on the Novocure NovoTTf100-A system. The registry data which I mentioned a few weeks ago is officially published now.  Other papers include an analysis of how patients respond over time. It shows that in half of the responders, the first MRI taken after starting treatment looked worse, then started looking better 5months later. The point is not to stop therapy too soon.  


IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://www.seminoncol.org/issue/S0093-7754(14)X0012-6


(Everything below this line is from VirtualTrials.com!)

Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740